Skip to main content
TipRanks
Go Ultimate75% OFF

Actuate Therapeutics, Inc. (ACTU) Stock Forecast & Price Target

57 Followers
See the Price Targets and Ratings of:

ACTU Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to Actuate Therapeutics, Inc. in the past 3 months

ACTU Stock 12 Month Forecast

$10.00▲(3631.34% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Actuate Therapeutics, Inc. in the last 3 months. The average price target is $10.00 with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 3631.34% change from the last price of $0.27.
Highest Price Target$10.00Average Price Target$10.00Lowest Price Target$10.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for ACTU
Price TargetArticle
H.C. Wainwright$15→$10buy3631.34%UpsideReiterated11/16/26
Rodman & Renshaw$6buy2138.81%UpsideInitiated07/30/26
Lucid Capital$6→$5buy1765.67%UpsideReiterated05/18/26
Craig-Hallum$12buy4377.61%UpsideReiterated05/12/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Actuate Therapeutics, Inc.

3 Months
Swayampakula Ramakanth
Swayampakula RamakanthH.C. Wainwright
Success Rate2/12 ratings generated profit
17%
Average Return
-30.69%

Copying Swayampakula Ramakanth's trades and holding each position for 3 Months would result in 16.67% of your transactions generating a profit, with an average return of -30.69% per trade.

1 Year
Swayampakula Ramakanth
Swayampakula RamakanthH.C. Wainwright
Success Rate0/12 ratings generated profit
0%
Average Return
-82.38%

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -82.38% per trade.

2 Years
Swayampakula Ramakanth
Swayampakula RamakanthH.C. Wainwright
Success Rate0/12 ratings generated profit
0%
Average Return
-89.29%

Copying Swayampakula Ramakanth's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -89.29% per trade.

ACTU Analyst Recommendation Trends

02468Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for ACTU
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy63322
Buy00000
Hold00000
Sell00000
Strong Sell00000
total63322

In the current month, ACTU has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ACTU average Analyst price target in the past 3 months is 10.00.

ACTU Financial Forecast

ACTU Earnings Forecast

Next quarter’s earnings estimate for ACTU is -$1.41 with a range of ― to ―. The previous quarter’s EPS was ―. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.

ACTU Stock Forecast FAQ

What is ACTU’s average 12-month price target, according to analysts?
Based on analyst ratings, Actuate Therapeutics, Inc.’s 12-month average price target is $10.00.
What is ACTU’s upside potential, based on the analysts’ average price target?
Actuate Therapeutics, Inc. has 3631.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ACTU a Buy, Sell or Hold?
Actuate Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Actuate Therapeutics, Inc.’s price target?
The average price target for Actuate Therapeutics, Inc. is $10.00. This is based on 1 12-month price targets, issued in the past 3 months. The highest analyst price target is $10.00, the lowest forecast is $10.00. The average price target represents a 3631.34% increase from the current price of $0.268.
What do analysts say about Actuate Therapeutics, Inc.?
Actuate Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of ACTU?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.